QC
CRBP icon

Quadrature Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Quadrature Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Sell
22,986
-6,903
-23% -$58.1K ﹤0.01% 1096
2025
Q4 		$243K Buy
+29,889
New +$369K ﹤0.01% 917

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quadrature Capital's CRBP Position: Q1 2026 in Review

Quadrature Capital reduced its Corbus Pharmaceuticals (CRBP) stake by 23% in Q1 2026, selling an estimated $58.1K and leaving 22,986 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Quadrature Capital first reported a position in CRBP in Q4 2025 and has held it in 2 quarters since. The position peaked at $243K in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Quadrature Capital held 22,986 shares of Corbus Pharmaceuticals worth $216K as of Q1 2026.
  • Quadrature Capital sold 6,903 Corbus Pharmaceuticals shares in Q1 2026, an estimated $58.1K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1096 holding.
  • Quadrature Capital first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Corbus Pharmaceuticals position peaked at $243K in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.